Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

ASXL1 mutations are recurrent in acute myeloid leukemia (AML), but it is unclear whether ASXL1 genotype might influence patient management. We analyzed frequency and impact in younger (15-59 years) and older (≥ 60 years) patients with primary or secondary disease. Overall, 9% had truncating mutations. Incidence was significantly lower in younger patients with primary than with secondary disease (4%, 12%; p = 0.03). In older patients it did not differ significantly (11%, 15%; p = 0.5). In univariate analysis, ASXL1-mutated patients had a worse outcome (5-year relapse 83% vs. 56%, p = 0.01; overall survival [OS] 6% vs. 22%, p = 0.02). However in multivariate analysis, ASXL1 mutations had no prognostic significance (for OS, p = 0.3), because age was a major confounding factor. The low incidence of mutations in younger patients with primary disease and the lack of significance in multivariate analysis indicate that there is a limited role for screening at diagnosis for ASXL1 mutations for the purpose of prognostic stratification.

Original publication

DOI

10.3109/10428194.2013.833332

Type

Journal article

Journal

Leuk Lymphoma

Publication Date

06/2014

Volume

55

Pages

1326 - 1331

Keywords

ASXL1, Acute myeloid leukemia, mutation, prognostic significance, Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Biomarkers, DNA Mutational Analysis, Female, Genotype, Humans, Incidence, Leukemia, Myeloid, Acute, Male, Middle Aged, Mutation, Patient Outcome Assessment, Prognosis, Repressor Proteins, Treatment Outcome, Young Adult